载有多西环素的pH敏感微粒作为潜在的针对牙周炎的特定部位的药物输送系统
Ardiyah Nurul Fitri Marzaman1, Ulfah Mahfufah1, Nurul Fauziah1
1Faculty of Pharmacy, Hasanuddin University, Makassar 90245, Indonesia.
ACS omega
|February 24, 2025
概括
这项研究开发了多西环素的pH敏感微粒,以改善牙周炎治疗的生物膜透. 新的水凝配方有效地将药物输送到感染部位,对关键细菌表现出显著的抗菌活性.
科学领域:
- 生物材料科学 生物材料科学
- 药物输送系统 药物输送系统
- 牙周治疗药物 牙周治疗药物
背景情况:
- 牙周炎的治疗受到牙周口袋中的细菌生物膜的挑战.
- 目前的疗法由于抗菌剂的透性较差和非特异性向而受到影响.
- 需要新的药物输送系统来增强生物膜透率和向输送.
研究的目的:
- 开发多西环素 (DOX) 的pH敏感微粒 (MP) 以提高生物膜透率.
- 创建一个in situ水凝配方,以有针对性地将DOX-MPs输送到牙周感染部位.
- 评估开发的系统的抗菌疗效和粘膜粘合性.
主要方法:
- 装有DOX的MPs是使用PLGA和奇托的双乳液技术制造的.
- MP的表征包括形态,颗粒大小,PDI,封装和药物加载效率.
- 在不同的pH条件下研究了药物释放动力学.
- 使用Pluronic F127/F68和HPMC.制备了一个in situ水凝配方.
- 抗菌活性在体外和体外对大肠杆菌和金黄色葡萄球菌进行了评估.
主要成果:
- DOX-MPs表现出球形形态 (3.54 ± 0.32 μm) 与良好的封装 (69.43%) 和药物负载 (14.81%).
- 在低pH条件下观察到药物加速释放,表明pH敏感性.
- 水凝配方在体温下表现出液体到凝的过渡以及良好的粘膜粘合.
- 活体研究显示,微生物数量,生物膜数量和代谢活性显著减少.
- DOX-MPs的抗菌疗效与免费的DOX相美.
结论:
- 在in situ水凝中配制的pH敏感的DOX-MPs为牙周炎治疗提供了一个有希望的策略.
- 该系统增强了针对性的药物输送和生物膜透.
- 该配方表现出有效的抗微生物活性和粘粘性质.
- 这种新的方法解决了牙周炎常规治疗方法的局限性.
更多相关视频
相关概念视频
Drug Delivery Systems: Different Types
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
Modified-Release Drug Delivery Systems: Influencing Factors
Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...


